Chi-Med announced that solepinib has been granted orphan drug status by the US Food and Drug Administration to treat primary immune thrombocytopenia. Immune thrombocytopenia is an autoimmune disorder that causes an increased risk of bleeding. Solepinib is a novel, highly selective oral spleen tyrosine kinase inhibitor.

Chi-Med announced that solepinib has been granted orphan drug status by the US Food and Drug Administration to treat primary immune thrombocytopenia. Immune thrombocytopenia is an autoimmune disorder that causes an increased risk of bleeding. Solepinib is a novel, highly selective oral spleen tyrosine kinase inhibitor.